logo
welcome
Reuters

Reuters

Roche targets more than $3 billion in annual obesity sales

Reuters
Summary
Nutrition label

78% Informative

Roche says three early-stage obesity and diabetes drug candidates from Carmot Therapeutics have potential of $3.6 billion in annual sales.

Last December Roche agreed to purchase unlisted Carmot for $2.7 billion upfront.

At least seven drugs in Roche 's development pipeline have peak sales potential of more than 3 billion francs .

VR Score

89

Informative language

98

Neutral language

17

Article tone

formal

Language

English

Language complexity

54

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links